The Cost-Effectiveness Of Saxagliptin When Added To Metformin And Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus In Spain.
نویسندگان
چکیده
■Diabetes complications, treatment-related adverse events and weight changes impact both on costs (table 3) and quality of life (impact on utility of micro-and macrovascular complications9,10, hypoglycaemias11 and weight12). All parameters used in the model were validated by a panel of clinical experts. THE COST-EFFECTIVENESS OF SAXAGLIPTIN WHEN ADDED TO METFORMIN AND SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN Sánchez-Covisa J1, Franch J2, Mauricio D3, López-Martínez N4, Chuang LH5, Capel M1. 1 AstraZeneca, Madrid, Spain; 2 Primary Health Care Center Raval Sud, Institut Català de la Salut, Barcelona, Spain; 3 Germans Trias i Pujol University Hospital, Barcelona, Spain; 4 Oblikue Consulting, Barcelona, Spain; 5 Pharmerit International, Rotterdam, The Netherlands. Poster no. PDB104
منابع مشابه
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
BACKGROUND Dipeptidyl peptidase-4 inhibitors improve glycaemic control in patients with type 2 diabetes mellitus when used as monotherapy or in combination with other anti-diabetic drugs (metformin, sulphonylurea, or thiazolidinedione). This 18-week, phase 3b, multicentre, double-blind, noninferiority trial compared the efficacy and safety of two dipeptidyl peptidase-4 inhibitors, saxagliptin a...
متن کاملCost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.
BACKGROUND The lack of adequate glycaemic control for patients with type 2 diabetes mellitus (T2DM), especially with existing second-line therapies, represents an unmet medical need. Of the newer therapies, the incretin-based medicines, such as saxagliptin, look promising to consolidate second-line pharmacotherapy. OBJECTIVE This study evaluates the long-term economic consequences of saxaglip...
متن کاملThe Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
OBJECTIVE This 24-week trial assessed the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes with inadequate glycemic control with metformin alone. RESEARCH DESIGN AND METHODS This was a randomized, double-blind, placebo-controlled study of saxagliptin (2.5, 5, or 10 mg once daily) or placebo plus a stable dose of metformin (1,500-2,500 mg) in 743 patients (...
متن کاملDPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2 diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive patients have demonstrated that DPP-4 inhibitors exert slightly less pronounced HbA(1c) reduction than metformin (with the advantage of better gastrointestinal tolerability) and similar glucose-lowering effects as with a thi...
متن کاملCost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China
OBJECTIVE This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone. METHODS Systematic literature reviews were performed to identify studies directly comparing SAXA+MET versus ACAR+MET, and to obtain diabetes-related events costs wh...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014